Association between SOX2 and OCT4 expression and the chemoradiation therapeutic response in undifferentiated non-keratinizing nasopharyngeal carcinoma
DOI:
https://doi.org/10.13181/mji.oa.203647Keywords:
nasopharyngeal carcinoma, OCT4, SOX2Abstract
BACKGROUND Self-renewal ability of cancer stem cells (CSS) is one of the possible causes for nasopharyngeal carcinoma (NPC) to relapse and metastasize. SOX2 and OCT4 are markers for expression of the embryonic stem cells and crucial for the progression of various malignancies. This study was aimed to analyze the association between SOX2 and OCT4 expression and chemoradiation therapeutic response in undifferentiated non-keratinizing NPC.
METHODS This cross-sectional study used archival data from Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital from January 2014 to December 2016. The outcomes were classified into good-response (complete and partial response) and poor-response groups (progressive and stable disease) based on response evaluation criteria in solid tumors (RECIST). SOX2 and OCT4 immunohistochemistry staining was performed using the initial specimen (before chemoradiation therapy) and positively expressing tumor cells were counted. Staining intensity was graded as: strong, moderate, weak, and negative. Strong and moderate staining was considered positive expression.
RESULTS 33 males and 8 females were included; 48% were ≥50 years old. Most of the patients had stage IV (n = 35) and several patients had stage II (n = 3) and III (n = 3). More cells expressed OCT4 in the good-response group than the poor-response group (61.3% versus 37.0%, p = 0.009). Meanwhile, there were less cells expressing SOX2 in the good-response group than the poor-response group (36.3% versus 61.1%, p = 0.097).
CONCLUSIONS This study suggests that OCT4 is a potential predictive marker for therapeutic response in patients with NPC.
Downloads
References
Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012;31(4):185-96. https://doi.org/10.5732/cjc.011.10328
Bell D, Petersson BF, El-Mofty SK, Gillison M, Lewis JS, Nadal A, et al. Tumors of the nasopharynx. In: Chan JKC, El-Naggar AK, Grandis JR, Takata T, Slootweg PJ. WHO classification of head and neck tumours. 4th ed. Lyon: IARC; 2017. p. 63-76.
Luo W, Li S, Peng B, Ye Y, Deng X, Yao K. Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One. 2013;8(2):e56324. https://doi.org/10.1371/journal.pone.0056324
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. https://doi.org/10.1016/j.ejca.2008.10.026
Ge N, Lin HX, Xiao XS, Guo L, Xu HM, Wang X, et al. Prognostic significance of Oct4 and Sox2 expression in hypopharyngeal squamous cell carcinoma. J Transl Med. 2010;8:94. https://doi.org/10.1186/1479-5876-8-94
Fu TY, Hsieh IC, Cheng JT, Tsai MH, Hou YY, Lee JH, et al. Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression. J Oral Pathol Med. 2016;45(2):89-95. https://doi.org/10.1111/jop.12335
Singh A, Srivastava AN, Akhtar S, Siddiqui MH, Singh P, Kumar V. Correlation of CD133 and Oct-4 expression with clinicopathological and demographic parameters in oral squamous cell carcinoma patients. Natl J Maxillofac Surg. 2018;9(1):8-13. https://doi.org/10.4103/njms.NJMS_60_17
Petersen JK, Jensen P, Sørensen MD, Kristensen BW. Expression and prognostic value of Oct-4 in astrocytic brain tumors. PLoS One. 2016;11(12):e0169129. https://doi.org/10.1371/journal.pone.0169129
Reers S, Pfannerstill AC, Maushagen R, Pries R, Wollenberg B. Stem cell profiling in head and neck cancer reveals an Oct-4 expressing subpopulation with properties of chemoresistance. Oral Oncol. 2014;50(3):155-62. https://doi.org/10.1016/j.oraloncology.2013.12.006
Dong Z, Liu G, Huang B, Sun J, Wu D. Prognostic significance of SOX2 in head and neck cancer: a meta-analysis. Int J Clin Exp Med. 2014;7(12):5010-20.
Bayo P, Jou A, Stenzinger A, Shao C, Gross M, Jensen A, et al. Loss of SOX2 expression induces cell motility via vimentin upregulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma. Mol Oncol. 2015;9(8):1704-19. https://doi.org/10.1016/j.molonc.2015.05.006
Tam WL, Ng HH. Sox2: masterminding the root of cancer. Cancer Cell. 2014;26(1):3-5. https://doi.org/10.1016/j.ccr.2014.06.024
Rizzino A, Wuebben EL. Sox2/Oct4: a delicately balanced partnership in pluripotent stem cells and embryogenesis. Biochim Biophys Acta. 2016;1859(6):780-91. https://doi.org/10.1016/j.bbagrm.2016.03.006
Qiao B, He B, Cai J, Yang W. The expression profile of Oct4 and Sox2 in the carcinogenesis of oral mucosa. Int J Clin Exp Pathol. 2014;7(1):28-37.
Stewart CL. Oct-4, scene 1: the drama of mouse development. Nat Genet. 2000;24(4):328-30. https://doi.org/10.1038/74129
Huch M, Rawlins EL. Cancer: tumours build their niche. Nature. 2017;545(7654):292-3. https://doi.org/10.1038/nature22494
Published
How to Cite
Issue
Section
License
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
